Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC):
Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)


Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the

Agilent Announces Optimized and Verified Method for Testing Over 100 PFAS Compounds:
Agilent Announces Optimized and Verified Method for Testing Over 100 PFAS Compounds


Agilent Technologies Inc. (NYSE: A) today announced the availability of an optimized and verified eMethod for PFAS Analysis in Water by LC/TQ for testing per- and polyfluoroalkyl substances (PFAS)

State of Delaware Selects Quidel for COVID-19 Testing Program at Schools
State of Delaware Selects Quidel for COVID-19 Testing Program at Schools


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is

Pfizer Announces New Investor Relations Leaderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces New Investor Relations Leader


Pfizer Inc. (NYSE: PFE) today announced that Christopher Stevo has joined the company as Senior Vice President and Chief Investor Relations Officer, reporting to Chief Corporate Affairs Officer

FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today U.S. Food and Drug Administration (FDA) clearance of the Dexcom

Quidel to Hold Fiscal Second Quarter 2021 Financial Results Conference Call on August 5th, 2021
Quidel to Hold Fiscal Second Quarter 2021 Financial Results Conference Call on August 5th, 2021


Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal second quarter 2021

Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021


Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2021 following the close of market on Thursday, August 5, 2021.



On the same day, at 2:00 pm Pacific

Louisville Nonprofits Receive $1.7 Million through The Humana Foundation’s Community Partners Program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Louisville Nonprofits Receive $1.7 Million through The Humana Foundation’s Community Partners Program


The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is awarding $1.7 million to nonprofit organizations in Louisville as part of its ongoing Community

Quidel Receives CE Mark for Savanna® Multiplex Molecular Analyzer and Respiratory Viral Panel
Quidel Receives CE Mark for Savanna® Multiplex Molecular Analyzer and Respiratory Viral Panel


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the

Humana Hiring up to 200 Virtual, Seasonal Positions in San Antonio: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Hiring up to 200 Virtual, Seasonal Positions in San Antonio


Leading health and well-being company Humana Inc. (NYSE: HUM) today announced it is looking to hire up to 200 virtual, seasonal Enrollment Representatives in and around San Antonio.



Humana’s

Montefiore Health System and Humana Sign Multi-Year Agreement Offering In-Network Coverage for Medicare Advantage Members: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Montefiore Health System and Humana Sign Multi-Year Agreement Offering In-Network Coverage for Medicare Advantage Members


Montefiore Health System, one of New York’s premier academic health systems, and leading health and well-being company Humana Inc. (NYSE: HUM), have signed a multi-year agreement that gives Humana

Humana Hiring up to 200 Seasonal Positions in Louisville: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Hiring up to 200 Seasonal Positions in Louisville


Leading health and well-being company Humana Inc. (NYSE: HUM) today announced it is looking to hire up to 200 seasonal Enrollment Representatives in and around Louisville.



Humana’s Medicare

Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2021 financial results after market close on Thursday, July 29, 2021. Management will hold a conference call

Humana Ranked No. 1 Among Health Insurers for Customer Experience: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Ranked No. 1 Among Health Insurers for Customer Experience


Humana ranked No. 1 among Health Insurers for customer experience (CX) quality in Forrester’s proprietary 2021 US CX Index™ survey. The ranking was based on responses from more than 85,000 US

TA Instruments Helps Laboratories Automate Thermal Analysis Workflows with New TRIOS AutoPilot Software
TA Instruments Helps Laboratories Automate Thermal Analysis Workflows with New TRIOS AutoPilot Software


Waters Corporation (NYSE:WAT) today introduced TRIOS AutoPilot software from its TA Instruments Division for its thermal analyzer product line. The software helps laboratory staff using TA’s

Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibitionhttps://www.cyansecurity.com/:
Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition


Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute. The paper

Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore’s Bioprocessing Technology Institute: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore’s Bioprocessing Technology Institute


Waters Corporation (NYSE:WAT) today announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology

Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline

DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes
DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of The Global Movement for Time in Range, an awareness

Waters Corporation Appoints Wei Jiang to Board of Directors: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters Corporation Appoints Wei Jiang to Board of Directors


Waters Corporation (NYSE: WAT) today announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021. Mr. Jiang currently serves as Executive Vice President and President

Pfizer Declares Third-Quarter 2021 Dividendhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Declares Third-Quarter 2021 Dividend


Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common

Humana Expanding its Commitment to Improving Physical and Mental Health Across North Carolina: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Expanding its Commitment to Improving Physical and Mental Health Across North Carolina


Leading health and well-being company Humana Inc. (NYSE: HUM) today announced it is expanding its commitment to the health and well-being of North Carolinians by more than doubling the number of

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)


Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will

Endurance Athlete Sébastien Sasseville to Ride Across Canada in Support of JDRF’s Access For All Campaign
Endurance Athlete Sébastien Sasseville to Ride Across Canada in Support of JDRF’s Access For All Campaign


Dexcom, Inc. and Tandem Diabetes Care, Inc. are thrilled to announce their support of Sébastien Sasseville, a Canadian endurance athlete and person living with type 1 diabetes, as he attempts to

Agilent Completes the InfinityLab Bio LC Portfolio :
Agilent Completes the InfinityLab Bio LC Portfolio


Agilent Technologies Inc. (NYSE: A) today announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release is central to the